Protalix BioTherapeutics (PLX) Income from Continuing Operations (2010 - 2026)

Protalix BioTherapeutics' (PLX) quarterly Income from Continuing Operations came in at 18388000.0 in Q1 2026, up 608.1% year-on-year from 2596822.45 in Q1 2025, and up 613.06% quarter-over-quarter from 3584000.0 in Q4 2025.

Protalix BioTherapeutics (PLX) Income from Continuing Operations (2010 - 2026) Analysis & Trends

Protalix BioTherapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 18388000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 608.1% year-over-year to 18388000.0 in Q1 2026; TTM through Mar 2026 was 17613000.0, a 108.29% increase from a year earlier, with the FY2025 full-year figure at 4684000.0, down 162.62% from the prior year.
  • Income from Continuing Operations rose to 18388000.0 in Q1 2026 per PLX's latest filing, from 3584000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 18388000.0 in Q1 2026 and bottomed at 20124000.0 in Q4 2023.
  • The 5-year median for Income from Continuing Operations is 2286000.0 (2022), against an average of 107117.65.
  • Across the five-year window, Income from Continuing Operations slumped 526.92% in 2023 and surged 608.1% in 2026, its largest moves.
  • Year by year, Income from Continuing Operations stood at 3210000.0 in 2022, then slumped by 526.92% to 20124000.0 in 2023, then soared by 153.7% to 10806000.0 in 2024, then slumped by 133.17% to 3584000.0 in 2025, then jumped by 613.06% to 18388000.0 in 2026.
  • Per Business Quant, the three latest PLX Income from Continuing Operations figures stand at 18388000.0 (Q1 2026), 3584000.0 (Q4 2025), and 2414000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -37.09 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -26.94 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 498.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Protalix BioTherapeutics 189.64 Mn 178.85 Mn 29.62 Mn 18.39 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 18.39 Mn
Dec 31, 2025 -3.58 Mn
Sep 30, 2025 2.41 Mn
Jun 30, 2025 395,000.00
Mar 31, 2025 -3.62 Mn
Dec 31, 2024 10.81 Mn
Sep 30, 2024 3.47 Mn
Jun 30, 2024 -2.20 Mn
Mar 31, 2024 -4.60 Mn
Dec 31, 2023 -20.12 Mn
Sep 30, 2023 -1.85 Mn
Jun 30, 2023 16.21 Mn
Mar 31, 2023 -3.13 Mn
Dec 31, 2022 -3.21 Mn
Sep 30, 2022 -3.57 Mn
Jun 30, 2022 -5.33 Mn
Mar 31, 2022 -2.29 Mn
Dec 31, 2021 -5.83 Mn
Sep 30, 2021 -4.30 Mn
Jun 30, 2021 -11.37 Mn